neuroendocrine tumors

BOSTON, Mass. — September 27, 2026 ITM Isotope Technologies Munich SE and Lumara Bio announced new real-world re-treatment and...

BOSTON, Mass. — September 14, 2026 Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its...

PARSIPPANY, N.J. and TEL AVIV, Israel, June 20, 2026 Teva Pharmaceutical Industries Ltd. has unveiled compelling new long-term data...

BOSTON, MA, June 18, 2026 Curium™ has secured a significant legal and commercial milestone after prevailing in a patent...

LOS ANGELES, California, June 1, 2026 ITM Isotope Technologies Munich SE announced new findings from its Phase 3 COMPETE...

MORRISTOWN, N.J., May 30, 2026 Whitehawk Therapeutics announced new real-world data at the 2026 American Society of Clinical Oncology...

February 25, 2026 – Garching / Munich, Germany ITM Isotope Technologies Munich SE, a leading radiopharmaceutical biotechnology company, has...

SAN DIEGO / Austin, Texas – October 23, 2025 Crinetics Pharmaceuticals, Inc. announced new results at the 2025 North...